77P - Surufatinib as third- or later-line treatment for patients with advanced small cell lung cancer

Background

Treatment options are very limited after the failure of two lines of therapy for small cell lung cancer (SCLC). Surufatinib (SUR) is a small-molecule tyrosine kinase inhibitor targeting VEGFRs 1-3, FGFR 1, and CSF-1R. This study aimed to evaluate the efficacy and safety of SUR as a third- or later-line treatment for SCLC.

Methods

This study planned to enroll 30 patients (pts) with histologically confirmed SCLC who had failed at least two lines of systemic chemotherapy. All pts received oral SUR 300 mg once daily until disease progression or unacceptable toxicity occurred. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, etc.

Results

As of October 20^th, 2024, fourteen pts had been enrolled. The median age was 61 years (range: 50-67), 71.4% of pts were males, and 71.4% of pts had extensive-stage disease. 50.0% of pts had metastases, with liver (35.7%) and brain (35.7%) being the most commonly involved sites. The number of prior treatment lines was 2 in 11 pts (78.6%) and 3 in 3 pts (21.4%). Fourteen pts were evaluable for tumor response. The confirmed ORR was 7.1%, and the DCR was 64.3%. With a median follow-up of 20.9 months (95% CI: 4.2-21.0), the median PFS was 2.9 months (95% CI: 1.4-4.8), and the median OS was 6.4 months (95% CI: 2.9-not reached [NR]). The most common treatment-related adverse events (TRAEs) were thrombocytopenia (4, 28.6%), nausea (4, 28.6%), and proteinuria (2, 14.3%), and most TRAEs were grade 1 or 2 except for one patient who experienced grade 3 hyperbilirubinemia. There were no cases with fatal outcome.

Conclusions

SUR showed potential antitumor activity and a manageable safety profile as a third- or later-line treatment for SCLC.

Clinical trial identification

ChiCTR2300071990.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.